Hims & Hers Health, Inc. $HIMS Shares Purchased by RFG Advisory LLC

Key Points

• RFG Advisory LLC boosted its stake in Hims & Hers by 371.7% in Q4, adding 62,316 shares to hold 79,081 shares valued at about $2.57 million, and institutional investors now own 63.52% of the stock.
• COO Michael Chi sold 97,289 shares on March 17 at an average price of $24.69 (≈$2.40M), and insiders have sold 204,857 shares worth $5.29M in the past 90 days, lowering insider ownership to 13.71%.
• Wall Street sentiment is mixed: the consensus rating is "Hold" with an average price target of $31.86 (ranges include JPMorgan's $35 overweight and Morgan Stanley's $21), while HIMS opened at $25.68 and was down about 4.5%.

RFG Advisory LLC raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 371.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,081 shares of the company's stock after purchasing an additional 62,316 shares during the period. RFG Advisory LLC's holdings in Hims & Hers Health were worth $2,568,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Hims & Hers Health by 16.7% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,766 shares of the company's stock valued at $1,295,000 after buying an additional 5,541 shares during the period. Strs Ohio raised its stake in Hims & Hers Health by 5.9% during the fourth quarter. Strs Ohio now owns 37,800 shares of the company's stock worth $1,227,000 after acquiring an additional 2,100 shares during the period. Cornerstone Planning Group LLC lifted its holdings in Hims & Hers Health by 305.9% in the fourth quarter. Cornerstone Planning Group LLC now owns 1,526 shares of the company's stock worth $50,000 after acquiring an additional 1,150 shares during the last quarter. Jennison Associates LLC lifted its holdings in Hims & Hers Health by 31.2% in the fourth quarter. Jennison Associates LLC now owns 17,960 shares of the company's stock worth $583,000 after acquiring an additional 4,276 shares during the last quarter. Finally, Bogart Wealth LLC boosted its stake in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after acquiring an additional 632 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In related news, COO Michael Chi sold 97,289 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the sale, the chief operating officer owned 407,282 shares of the company's stock, valued at $10,055,792.58. The trade was a 19.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Irene Becklund sold 5,529 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $136,511.01. Following the sale, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 204,857 shares of company stock valued at $5,285,706. 13.71% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HIMS shares. JPMorgan Chase & Co. initiated coverage on Hims & Hers Health in a report on Friday, April 24th. They issued an "overweight" rating and a $35.00 price target on the stock. Morgan Stanley dropped their target price on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 24th. BTIG Research downgraded shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a report on Tuesday, February 24th. TD Cowen lowered their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating for the company in a research report on Friday, March 27th. Finally, Evercore set a $24.00 price objective on shares of Hims & Hers Health in a report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $31.86.

Hims & Hers Health Stock Down 4.5%

HIMS opened at $25.68 on Friday. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock has a market cap of $5.85 billion, a P/E ratio of 50.35, a P/E/G ratio of 3.67 and a beta of 2.43. The stock's 50 day moving average price is $22.56 and its 200 day moving average price is $29.75.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to analysts' expectations of $619.48 million. During the same period last year, the firm earned $0.11 EPS. The firm's revenue was up 28.4% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.53 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.